Rios Hector F, Bashutski Jill D, McAllister Bradley S, Murakami Shinya, Cobb Charles M, Patricia Chun Yong-Hee, Lin Zhao, Mandelaris George A, Cochran David L
Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI.
Department of Periodontology, Oregon Health and Science University, Portland, OR.
Clin Adv Periodontics. 2015 Feb;5(1):40-46. doi: 10.1902/cap.2015.140052.
Focused Clinical Question: Can emerging technologies for periodontal regeneration become clinical reality? Summary: Emerging technologies are presenting options to hopefully improve the outcomes of regeneration in challenging clinical scenarios. Cellular allografts represent a current technology in which cells and scaffolds are being delivered directly to the periodontal lesion. Recombinant human fibroblast growth factor 2 and teriparatide (parathyroid 1-34) have each been tested in controlled prospective human randomized clinical trials, and both have been shown to have potential for periodontal regeneration. These examples, as well as other emerging technologies, show promise for continued advancement in the field of periodontal regenerative therapy. Conclusions: At present, there are indications that emerging technologies can be used successfully for periodontal regeneration. Case reports and clinical trials are being conducted with a variety of emerging technologies. However, many are yet to be approved by a regulatory agency, or there is a lack of evidence-based literature to validate their expanded use.
用于牙周再生的新兴技术能否成为临床现实?总结:新兴技术正在提供一些选择,有望在具有挑战性的临床情况下改善再生效果。细胞同种异体移植物是一种当前的技术,其中细胞和支架被直接输送到牙周病变部位。重组人成纤维细胞生长因子2和特立帕肽(甲状旁腺素1-34)均已在对照前瞻性人类随机临床试验中进行了测试,并且都已显示出具有牙周再生的潜力。这些例子以及其他新兴技术,为牙周再生治疗领域的持续进步展现出了前景。结论:目前,有迹象表明新兴技术可以成功用于牙周再生。正在使用各种新兴技术进行病例报告和临床试验。然而,许多技术尚未获得监管机构的批准,或者缺乏循证文献来验证其广泛应用。